Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 17 of 17 publications.

Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Hancock H, Brockbank J, Theodorou E, Brodtkorb TH. Survival analysis methods used in immuno-oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S92. doi: 10.1016/j.jval.2022.09.451

Hancock H, Brockbank J, Brodtkorb TH, Lucherini S, Russell J. A review of cure assumptions implemented in early-stage oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S148. doi: 10.1016/j.jval.2022.09.714

Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3

Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097

Brockbank J, Krause T, Moss E, Pedersen AM, Morup MF, Ahdesmaki O, Vaughan J, Brodtkorb T-H. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes. 2021 Mar 18;19(1):94. doi: 10.1186/s12955-021-01723-x

Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6

Sierra J, Mareque M, Montesinos P, Guinea JM, Font P, Oyaguez I, Brockbank J, Candini D, Llinares J, Soto J, de la Fuente A. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain. Poster presented at the 2020 Virtual European Hematology Association; June 2020.

Gallagher J, Russell L, McAlister M, Brockbank J. Impact of gemtuzumab ozogamicin on the Irish healthcare system. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Basarir H, Brockbank J, Knight C, Wolowacz S. The inclusion of the utility values for carers and family members in HTAs: a case study of recent NICE appraisals in the UK. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA. [abstract] Value in Health Regional Issues. 2019 May; 22(Suppl 2):S330.

Mokgokong R, Mamolo C, Cappelleri J, Knight C, Brockbank J, Cawson M, Dombre H, Castaigne S. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy (daunorubicin and cytarabine) for first-line treatment of acute myeloid leukaemia. Poster presented at the 2019 British Society for Haematology Meeting; April 1, 2019. Glasgow, Scotland.

Walter R, Mamolo C, Welch V, Brockbank J, Cawson M, Knight C, Wilson M. Budget-impact analysis for gemtuzumab ozogamicin in CD33+ acute Myeloid Leukemia. Poster presented at the XXXVII World Congress International Society of Hematology (ISH); September 14, 2018. Vancouver, Canada.

Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4

Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or total knee replacement. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Rosseli D, Rueda J, Wolowacz SE, Brockbank JA, Abeysinghe SS. Cost-effectiveness of dabigatran compared with warfarin, apixaban, rivaroxaban and low molecular weight heparins for the treatment and secondary prevention of venous thromboembolism in Colombia. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.

Wolowacz S, Brockbank J, Sunderland TJ, Gonschior AK. Cost-effectiveness of dabigatran etexilate for the secondary prevention of recurrent deep vein thrombosis and pulmonary embolism in the United Kingdom. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A526.

Pearson IV, Wolowacz SE, Irving AH, Brockbank JA, Chubb B, Gundgaard J, Briggs A, Davies M. A systematic review of recent data describing the risk of complications in type 1 diabetes mellitus patients. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A496-7.